Literature DB >> 9632610

Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans.

A Rudin1, E L Johansson, C Bergquist, J Holmgren.   

Abstract

Although nasal vaccination has emerged as an interesting alternative to systemic or oral vaccination, knowledge is scarce about the immune responses after such immunization in humans. In the present study, we have compared the kinetics and organ distribution of the antibody responses after nasal and oral vaccination. We immunized female volunteers nasally or orally with cholera toxin B subunit (CTB) and determined the specific antibody levels in serum and nasal and vaginal secretions, as well as the number of circulating antibody-secreting cells, before immunization and 1, 2, 3, 6, and 26 weeks thereafter. Nasal vaccination induced 9-fold CTB-specific immunoglobulin A (IgA) and 56-fold specific IgG antibody increases in nasal secretions, whereas no significant IgA increase was seen after oral vaccination. Both oral and nasal vaccination resulted in 5- to 6-fold CTB-specific IgA and 20- to 30-fold specific IgG increases in vaginal secretions. Strong serum responses to CTB were also induced by both routes of vaccination. A notable difference between nasal and oral vaccination was that the nasal route elicited a specific antibody response with a later onset but of much longer duration than did the oral route. We conclude from this study that the nasal route is superior to the oral route for administering at least nonliving vaccines against infections in the upper respiratory tract, whereas either oral or nasal vaccination might be used for eliciting antibody responses in the female genital tract.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9632610      PMCID: PMC108357     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine.

Authors:  A Kantele
Journal:  Vaccine       Date:  1990-08       Impact factor: 3.641

2.  Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development.

Authors:  J Sanchez; J Holmgren
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

3.  Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine.

Authors:  P L Ogra; D T Karzon
Journal:  J Immunol       Date:  1969-06       Impact factor: 5.422

Review 4.  The common mucosal immune system and current strategies for induction of immune responses in external secretions.

Authors:  J Mestecky
Journal:  J Clin Immunol       Date:  1987-07       Impact factor: 8.317

5.  A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells.

Authors:  C C Czerkinsky; L A Nilsson; H Nygren; O Ouchterlony; A Tarkowski
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.

Authors:  A M Svennerholm; M Jertborn; L Gothefors; A M Karim; D A Sack; J Holmgren
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

Review 7.  Actions of cholera toxin and the prevention and treatment of cholera.

Authors:  J Holmgren
Journal:  Nature       Date:  1981-07-30       Impact factor: 49.962

8.  Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection.

Authors:  T W Cotter; Q Meng; Z L Shen; Y X Zhang; H Su; H D Caldwell
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

9.  Human immune responses to influenza virus vaccines administered by systemic or mucosal routes.

Authors:  Z Moldoveanu; M L Clements; S J Prince; B R Murphy; J Mestecky
Journal:  Vaccine       Date:  1995-08       Impact factor: 3.641

10.  Oral vaccination. Identification of classes of proteins that provoke an immune response upon oral feeding.

Authors:  H J de Aizpurua; G J Russell-Jones
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  33 in total

1.  Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans.

Authors:  E L Johansson; L Wassén; J Holmgren; M Jertborn; A Rudin
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

2.  Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit.

Authors:  A Rudin; G C Riise; J Holmgren
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

3.  Nasal vaccination induces protective immunity without immunopathology.

Authors:  T Hussell; I R Humphreys
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

4.  Immune responses elicited in mice with recombinant Lactococcus lactis expressing F4 fimbrial adhesin FaeG by oral immunization.

Authors:  Shujie Liu; Yongming Li; Ziwei Xu; Yicheng Wang
Journal:  Vet Res Commun       Date:  2010-06-09       Impact factor: 2.459

Review 5.  Evaluation of events occurring at mucosal surfaces: techniques used to collect and analyze mucosal secretions and cells.

Authors:  Bruno Guy
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

6.  Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.

Authors:  Kingston H G Mills; Catherine Cosgrove; Edel A McNeela; Amy Sexton; Rafaela Giemza; Inderjit Jabbal-Gill; Anne Church; Wu Lin; Lisbeth Illum; Audino Podda; Rino Rappuoli; Mariagrazia Pizza; George E Griffin; David J M Lewis
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

7.  Cholera toxin B-subunit gene enhances mucosal immunoglobulin A, Th1-type, and CD8+ cytotoxic responses when coadministered intradermally with a DNA vaccine.

Authors:  Alba E Sanchez; Guillermo Aquino; Pedro Ostoa-Saloma; Juan P Laclette; Leticia Rocha-Zavaleta
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

8.  Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.

Authors:  X Shen; T Lagergård; Y Yang; M Lindblad; M Fredriksson; J Holmgren
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

9.  Tonsillar application of formalin-killed cells of Streptococcus sobrinus reduces experimental dental caries in rabbits.

Authors:  T Fukuizumi; H Inoue; T Tsujisawa; C Uchiyama
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

10.  Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans.

Authors:  Lotta Wassen; Marianne Jertborn
Journal:  Clin Diagn Lab Immunol       Date:  2005-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.